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ABSTRACT 
Objective: The present work was aimed at preparation of mesalazine microspheres by a non-aqueous solvent evaporation method using eudragit S 
100 and eudragit L 100 as pH dependent polymers for colon targeting.  
Methods: The ratio of drug to polymer was varied and the effect of formulation variables revolutions per minute (RPM) (1000, 1500, 2000 and 
2500) and concentration of span 80 (1%, 1.5%, 2% and 2.5%) were studied. Prepared microspheres were evaluated for particle size, percent drug 
entrapment, granular analysis, in vitro drug release studies, Fourier transformed infrared spectroscopy (FT-IR) Differential Scanning Calorimetry 
(DSC), X-ray diffraction (XRD) and scanning electron microscopy (SEM) studies. 
Results: Particle size has decreased and percent drug entrapment had increased with increase in RPM in all formulations. When the span 80 
concentration increased, the particle size of the microsphere formulations increased and percent drug entrapment decreased in eudragit S 100 
microspheres; whereas in eudragit L 100 microspheres, as the concentration of span 80 increased, the particle size of the microsphere formulations 
decreased. The prepared microspheres sustained the drug release over a period of 12 h. 
Conclusion: Thus eudragit S 100 and eudragit L 100 microspheres could constitute a promising approach for colon-specific and sustained delivery 
of mesalazine for the treatment of inflammatory bowel disease. 
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Oral drug delivery system is one of the frontier areas of delivering a 
drug with the cost-effectiveness of dosage form and treatment, 
patient compliance, optimum drug delivery and bioavailability [1]. 
There has been a remarkable improvement in the field of novel drug 
delivery systems. Carrier technology is an approach for drug 
delivery by the union of the drug to a carrier particle such as 
microspheres, nanoparticles, liposomes, etc. which modulates the 
release and absorption characteristics of the drug [2]. 
Colon-specific drug delivery systems have gained increasing attention 
for the treatment of diseases such as Crohn’s disease, ulcerative colitis 
and irritable bowel syndrome [3]. Single unit dosage forms such as 
tablets and capsules for modified release colonic delivery suffer from 
problems such as unpredictable gastric emptying, gastrointestinal (GI) 
transit variations resulting from inter-subject variability in transit 
patterns and incomplete drug delivery in GI tract due to the risk of not 
dissolving the polymer coat on the large, low surface area coated 
tablets. On the other hand, multi-particulate drug delivery system for 
colonic delivery shows several advantages over single-unit dosage 
forms. Being of smaller size, it is expected to provide less inter and 
intra-individual variability, more rapid and uniform gastric emptying, 
more uniform dispersion and reproducible transit through GI tract [4, 
5]. However, in microparticulate delivery systems, it is challenging to 
develop a colon-targeted sustained-release dosage form. Microspheres 
are homogeneous, monolithic particles which improve the treatment 
by providing localization of the drug at the site of action and by 
prolonging the drug release [6]. It suffers from the risk of early 
dissolution and release of the drug before reaching the colon due to its 
large surface area [7, 8]. 
Mesalazine (5-aminosalicylic acid, 5-ASA) is widely used in long-
term treatment of ulcerative colitis by its topical mode of action on 
the inflammation in colonic mucosa. In order to achieve effective 
oral mesalazine treatment with minimal side effect and acceptable 
patient compliance, the delivery system has to overcome many 
obstacles. The effective use of the majority of the currently marketed 
mesalazine formulations requires multiple daily dosing with up to 
12 tablets or capsules [9, 10].  
Upon oral administration, mesalazine exhibits rapid and nearly 
complete absorption from the upper intestine, resulting not only in 
systemic side effects but also in lowering the dose reaching the colon 
with the subsequently decreased probability of therapeutic success 
[11]. In ulcerative colitis, inflammation is observed in all regions of 
the colon. Accordingly, in order to overcome these problems, in 
formulating mesalazine in a successful delivery system, it is 
important to minimise 5-ASA release in the upper gastrointestinal 
tract and to localize mesalazine release in the colon in a sustained 
release manner. If mesalazine is released in a pulsatile manner in the 
ascending colon, it would be diluted during its passage in the colon, 
consequently, a scarce concentration of mesalazine could be 
delivered to the transverse and descending colon resulting in 
reduced clinical effectiveness. 
This is more difficult in the case of mesalazine due to its 
physiochemical properties. mesalazine exhibits amphoteric property, 
its solubility is increased at acidic pH values (pH<2) in the stomach 
and at more alkaline values (pH>5.5) in the lower part of the small 
intestine. This necessitates the development of pH-dependent, colon-
targeted, sustained release mesalazine microspheres. The goal of this 
work was to prepare mesalazine microspheres by a non-aqueous 
solvent evaporation method employing pH-dependent polymers like 
eudragitS100 and eudragit L 100. 
MATERIALS AND METHODS 
Materials 
Mesalazine was purchased from BEC Chemicals, Mumbai. Eudragit S 
100 and Eudragit L 100 were procured from Yarrow Chem Products, 
Mumbai. Magnesium stearate was purchased from Central Drug House 
Pvt. Limited, New Delhi. Acetone and liquid paraffin heavy was 
purchased from Rankem, New Delhi. Span 80 was purchased from NR 
CHEM, Mumbai. All other reagents used were of analytical grade.  
Experimental methods 
Preparation of microspheres 
Microspheres containing mesalazine were prepared by a non-
aqueous solvent evaporation technique. Mesalazine and the 
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specified amount of magnesium stearate were dispersed in 
acetone to which eudragit S 100 was previously dissolved. The 
resulting suspension was added at once to a specified amount of 
liquid paraffin containing 2% (v/v) span 80 and stirred at 1500 
revolutions per minute (RPM) for 3 h using a mechanical stirrer 
under ambient conditions (table 1). Stirring was continued until 
the organic solvent evaporated completely. The microspheres 
were filtered, washed with n-hexane, dried overnight and then 
stored in desiccators until further use [12]. The same procedure 
was repeated using eudragit L 100. 
 
Table 1: Batch specifications of preliminary formulations 
S. No. Formulation code Drug: polymer ratio Stirring speed (RPM) Emulsifier Concentration (%) 
1 F1 1:1 1500 2 
2 F2 1:2 1500 2 
3 F3 1:3 1500 2 
4 F4 1:4 1500 2 
5 F5 1:5 1500 2 
6 F6 1:1 1500 2 
7 F7 1:2 1500 2 
8 F8 1:3 1500 2 
9 F9 1:4 1500 2 
10 F10 1:5 1500 2 
 
FT-IR studies 
The drug and polymer interactions were studied by Fourier 
transform infrared spectroscopy by KBr disc method. The spectra 
were recorded for the pure drug, polymer and the physical mixture 
of drug and polymer in the ratio 1:1 at the scanning range of 400-
4000 cm-1 using FTIR-8400S, spectrophotometer (SHIMADZU, 
Japan). 
DSC studies 
The DSC analysis of pure drug, polymer and the physical mixture of 
drug and polymer were carried out using differential scanning 
calorimeter (PERKIN ELMER-Pyris 1). Samples of about 5 mg was 
placed in a 50μl perforated aluminium pan and sealed. Heat runs for 
each sample were set from 5 ⁰C to 300 ⁰C using nitrogen as purging 
gas and samples were analyzed. 
XRD studies  
Powder XRD of mesalazine, eudragit S-100, eudragit L-100, 
Formulation mixture of mesalazine with eudragit S-100, 
Formulation mixture of mesalazine with eudragit L-100 was 
recorded using Bruker AXS D8 Advance diffractometer with Si(Li) 
PSD detector. The operation data were: measuring circle diameter-
435, 500 and 600 mm predetermined; angle range-360⁰; X-ray 
source-Cu, wavelength 1.5406A⁰. 
Characterization of prepared microspheres 
Micromeritic studies 
The microspheres were characterized for their micromeritic properties 
such as tap density, bulk density, Carr’s index, Hausner’s ratio and angle 
of repose. All the analysis was carried out in triplicate [13]. 
Yield of microspheres 
The percentage yield of microspheres was calculated by the 
following formula, 
% yield 
Actual weight of product
Total weight of drug and excipient
× 100 
Scanning electron microscopy 
The surface morphology of prepared microspheres was observed 
under scanning electron microscope (JEOL, JSM-T, Japan). Dry 
microspheres were placed on an electron microscope brass stub and 
coated with gold to a thickness of about 200 A° using a sputter 
coater in an ion sputter. Pictures of the microspheres were taken by 
randomly scanning the stub with the help of SEM analyzer. 
Particle size determination 
The microspheres were observed under 100X magnification in an 
optical microscope (Olympus LITE image) and an average of 100 
particles was counted. 
Drug entrapment efficiency 
Accurately weighed the quantity of microspheres equivalent to 100 
mg of mesalazine was taken in 100 ml volumetric flask and 
dissolved in 50 ml of 25% sodium acetate solution using sonication 
for 15 min and the volume was made up to 100 ml with 25% sodium 
acetate solution. The resulting solution was diluted suitably with 
water and filtered through Whatman filter paper No: 41. The 
absorbance of the resulting solution was measured at 240 nm, using 
distilled water as a blank. All the analysis was carried out in 
triplicate. The percentage drug entrapment was determined using 
the following equation, 
% drug entrapment efficiency 
=
Amount of drug actually present 
Theoritical drug loaded expected
× 100 
In vitro drug release studies 
In vitro drug release was studied using dissolution test apparatus USP 
type I method (rotating basket method). The drug loaded 
microspheres equivalent to 100 mg of mesalazine were introduced 
into 900 ml of dissolution medium which was maintained at 37±0.5⁰C 
and stirred at 100 rpm. The dissolution was carried out in 0.1N 
hydrochloric acid for first 2 h followed by 4.5pH acetate buffer for next 
2 h and 7.4 pH buffers containing rat fecal content for next 8 h to 
mimic the GIT transit to colon region [14]. 5 ml of the aliquot was 
withdrawn at regular predetermined intervals and sink conditions 
were maintained throughout the study by replacing an equal volume 
of fresh dissolution medium. The samples were diluted suitably with 
distilled water and analysed spectro-photometrically at 240 nm. All 
the analysis was carried out in triplicate. 
Drug release kinetics 
Data obtained from in vitro drug release studies were fitted to 
various kinetic models like zero-order, 1st order, Higuchi, 
Korsemeyer and Peppas using PCP Disso V2 software to predict the 
drug release mechanism. 
Stability studies 
Based on the International Conference on Harmonization (ICH) 
guidelines [15, 16] the stability studies were carried out in an 
environmental chamber (Tempo Instruments, India). Microsphere 
formulations F13 and F20 were stored at 40 °C±2 °C and 75%±5% 
RH for a period of 6 mo. At intervals of 0, 2, 4 and 6 mo for 
accelerated storage condition, the samples were tested for changes 
in physical appearance and drug content. 
RESULTS AND DISCUSSION 
FTIR studies 
Eudragit S 100 (in fig. 1a)showed hydroxyl group stretching (-OH) at 
2989 cm-1, alkyl group (CH-R) stretching at 2997 cm-1, the ester 
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linkage (C=O-O-R) stretching at 1726 cm-1, carboxylic acid (C=O-OH) 
stretching was observed at 1708 cm-1, alkyl group (CH-R) bending at 
1386, 1448, 1483 cm-1 and carboxylic acid bending peaks at 1159, 
1188, 1263 cm-1. Fig. 1b represents the FT-IR spectra of eudragit L 
100. The characteristic peaks of eudragit L 100 are hydroxyl group 
stretching (-OH) at 3494 cm-1, alkyl group (CH-R) stretching at 2993 
cm-1, the ester linkage (C=O-O-R) stretching at 1784 cm-1, carboxylic 
acid (C=O-OH) stretching at 1724 cm-1, alkyl group (CH-R) bending 
at 1384, 1448, 1487 cm-1 and carboxylic acid bending peaks at 1161, 
1186, 1261 cm-1. Magnesium stearate showed absorptions peaks at 
2914 and 2486 cm-1 due to C-H stretching of the molecule. The other 
bands located at 1581, 1476 cm-1are due to the COO-group 
stretching (in fig. 1c).  
The characteristic peaks of mesalazine are carboxylic acid stretch R-
C=O-OH with peaks at 3342 and 1315 cm-1, C=O stretch at 1789 cm-
1,-C6H5 aromatic ring stretch at 1645 cm-1,–C-H (aromatic) stretch at 
1450 cm-1 and-C=C (aromatic) at 1490 cm-1. The bending peaks of 
meta, para-substituted benzene was observed at 811 cm-1 and the R-
NH2 bending peak was observed at 686 cm-1(fig. 1d). FT-IR spectra of 
physical mixture of mesalazine with eudragit S 100 and eudragit L 
100 showed characteristic peaks of carboxylic acid stretch R-C=O-
OH, observed at 3409 and 1315 cm-1, C=O stretch at 1789 cm-1,-C6H5 
aromatic ring stretch at 1645 cm-1,–C-H (aromatic) stretch at 1452 
cm-1 and-C=C (aromatic) stretch at 1490 cm-1. The above results 
confirmed the absence of drug interaction within the polymers (fig. 
1e and 1f). 
 
 
Fig. 1: FT-IR Graphs of a) eudragit S 100; b) eudragit L 100; c) Mg stearate; d) mesalazine; e) mesalazine+eudragit S 100; f) 
mesalazine+eudragit L 100 
 
DSC studies 
DSC thermogram of pure drug mesalazine (fig. 2a) showed a 
characteristic exothermic peak at 294.52 °C, which was within 
the range of melting point of mesalazine. Eudragit L-100 and 
eudragit S-100 exhibited a similar exothermic peak at 239.84 °C 
and 222.86 °C respectively (fig. 2b and 2c). The observed 
melting point range was found to be in close proximity to the 
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values reported. Mesalazine peak was found at 287.11⁰C in a 
physical mixture of mesalazine with eudragit S-100(fig. 2d) and 
in a physical mixture of mesalazine with eudragit L-100, a 
characteristic peak was observed at 289.11⁰C (fig. 2e). This 
study confirmed that there was no interaction between the drug 
and polymers used. 
 
 
Fig. 2: DSC Curves of a) mesalazine; b) eudragit L 100; c) eudragit S 100; d) mesalazine+eudragit S 100; e) mesalazine+eudragit L 100 
 
XRD studies 
The powder XRD curves were represented in the fig. 3. The 2θ 
values from the powder XRD studies for mesalazine was found to 
be 14.956⁰ (fig. 3a) and a sharp intense peak indicated the 
crystallinity of the drug. The 2θ value of eudragit L-100 was found 
to be 42.709⁰ (fig. 3b) indicating its crystalline nature. The 2θ 
value of eudragit S-100 was found to be 14.487⁰ (fig. 3c) and 
confirmed its amorphous nature by a broad peak. A physical 
mixture of mesalazine with Eudragit S-100 showed a sharp intense 
peak at 15.167⁰ (represented in the fig. 3d) and that of mesalazine 
with eudragit L-100 showed a sharp peak at 15.084⁰ (represented 
in the fig. 3e) indicating that the drug and the polymer existed in 
the crystalline state. 
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Fig. 3: XRD Curves of a) mesalazine; b) eudragit L 100; c) eudragit S 100; d) mesalazine+eudragit S 100; e) mesalazine+eudragit L 100 
characterization of mesalazine microspheres 
 
The percentage yield ranged from 87.96% to 99.78% for eudragit 
S 100 microspheres and 86.79% to 95.86% for eudragit L 100 
microspheres. Particle size was found to be in the range of 
265.26±1.9μm to 301.21±0.2μm with eudragit S 100 microspheres 
and 295.09±2.8μm to 367.93±2.3μm with eudragit L 100 
microspheres. The percent drug entrapment was found to be in 
the range of 85.56% to 99.12% for all formulations of eudragit S 
100 microspheres and 79.52% to 96.54% for formulations made 
with eudragit L 100. The granular analysis of the prepared 
microspheres was performed and flow property was found to be 
best for formulation F5 (22⁰ 43) using eudragit S 100 and for 
formulation F8 (24⁰ 93) using eudragit L 100. Bulk density was 
found to be least for formulation F10 at 0.3526g/cc and maximum 
for formulation F6 at 0.4968g/cc. Tap density was found to be in 
the range of 0.4850g/cc to 0.7443g/cc for all the prepared 
microsphere formulations. The bulkiness was observed to be in 
the range of 2.0128 to 2.8360. The Carr’s index was found to be in 
the range of 20% to 46.1% and Hausner’s ratio was found to be in 
the range of 1.25 to 1.85 for all the microsphere formulations. The 
results were shown in table 2. 
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F1 95.7±0.90 275.35±1.6 85.56±0.36 0.385±0.04 0.616±0.04 1.61±0.5 25⁰ 05 37.5±0.3 2.59±0.61 
F2 87.9±0.65 290.86±3.2 90.11±0.45 0.363±0.03 0.485±0.06 1.33±0.6 26⁰ 15 25.1±0.4 2.74±0.54 
F3 89.9±0.74 301.21±0.2 92.56±0.98 0.428±0.02 0.588±0.03 1.37±0.4 28⁰ 49 27.28±0.2 2.33±0.32 
F4 91.5±0.63 270.85±2.5 95.39±0.35 0.460±0.04 0.575±0.04 1.25±0.3 25⁰ 96 20.3±0.3 2.17±0.45 
F5 99.7±0.84 265.26±1.9 99.12±0.47 0.456±0.03 0.580±0.05 1.27±0.5 22⁰ 43 21.4±0.4 2.19±0.24 
F6 86.7±0.37 295.09±2.8 79.52±0.55 0.496±0.05 0.744±0.03 1.49±0.6 26⁰ 45 33.25±0.6 2.01±0.30 
F7 88.9±0.91 367.93±2.3 84.65±0.87 0.389±0.03 0.678±0.04 1.74±0.5 27⁰ 58 42.58±0.3 2.56±0.80 
F8 95.8±0.57 280.47±0.5 96.54±0.49 0.406±0.02 0.676±0.04 1.66±0.4 24⁰ 93 39.99±0.2 2.46±0.30 
F9 93.7±0.69 336.21±2.8 95.65±0.34 0.401±0.05 0.685±0.03 1.70±0.4 30⁰ 57 41.38±0.4 2.49±0.20 




Scanning electron microscopy of the formulations revealed that the 
surface morphology of the prepared microspheres was found to be 
spherical. The surface of the spheres was rough with abrasions on it 
(fig. 4a and 4b). 
 
 
Fig. 4a: Microspheres of eudragit S-100 
 
In vitro drug release studies 
The percentage drug release was found best in formulation F5 with 
101.45% release and least drug release was observed in formulation 
F2 with 94.39% at the end of 11th h for microspheres prepared with 
eudragit S 100. The drug release was found best in formulation F8 
with 99.69% and least drug release was observed with 96.66% in 
formulation F10 to the end of 11 h for microspheres prepared with 
eudragit L 100. The plot for cumulative drug release profiles for all 
the mesalazine formulations prepared using eudragit S 100 and L 
100 was shown in the fig. 5 and 6. The drug release for the 
formulations was found to be less than 30% till the end of 4th hour 
after which there is a rapid release of drug by the end of 11 h. Even if 
the microspheres did not burst, large swelling occurred and thus 
increased matrix porosity. These findings comply well with the 
higher drug to polymer ratio used in formulations [17]. This release 
shows the pH sensitivity of the polymer which releases the drug 
only in the colon region. 
 
 
Fig. 4b: Microspheres of eudragit L-100 
 
 
Fig. 5: Drug release profile of formulations with eudrait S-100 (n=3) 
Deveswaran et al. 
Int J App Pharm, Vol 9, Issue 4, 2017, 1-9 
7 
 
Fig. 6: Drug-release profile of formulations with eudragit L-100 (n=3) 
 
Drug release kinetics 
The best fit model was found to be Peppas for formulations F1, F2, 
F5, F7, F8 F9 and F10, whereas formulations F3, F4, F6 showed zero 
order release kinetics.  
Effect of process variables on formulations 
Among the mesalazine microspheres prepared using Eudragit S 100, 
formulation F5 was selected as the best and from the formulations 
prepared using Eudragit L 100, formulation F8 was selected as the 
best based on their in vitro drug release profile. The effects of 
process variables on these 2 formulations F5 and F8 were studied. 
The formulation variables tested were a. The concentration of Span 
80 and b. RPM (table 3 and 4). 
Effect of concentration of span 80 on mesalazine loaded 
eudragit S 100 microspheres 
Three formulations F11, F12 and F13 were prepared using 
mesalazine and eudragit S 100 in the ratio of 1:5 and varying span 
80 concentration by 1%, 1.5% and 2.5% but fixed RPM at 1500. As 
the concentration of span 80 increased, the particle size of the 
microsphere formulations increased, whereas the percent drug 
entrapment decreased. This could be due to the increase in the 
viscosity of the medium. 
 
Table 3: Effect of variable parameters on formulation with eudragit S-100 
S. No. Formulation code Drug: polymer ratio Stirring speed Emulsifier concentration (%) 
1 F11 1:5 1500 1 
2 F12 1:5 1500 1.5 
3 F13 1:5 1500 2.5 
4 F14 1:5 1000 2 
5 F15 1:5 2000 2 
6 F16 1:5 2500 2 
 
Table 4: Effect of variable parameters on formulation with eudragit L-100 
S. No. Formulation code Drug: polymer ratio Stirring speed Emulsifier concentration (%) 
1 F17 1:3 1000 2 
2 F18 1:3 2000 2 
3 F19 1:3 2500 2 
4 F20 1:3 1500 1 
5 F21 1:3 1500 1.5 
6 F22 1:3 1500 2.5 
 
Effect of RPM on mesalazine loaded eudragit S 100 microspheres 
Three formulations F14, F15 and F16 were prepared using 
mesalazine and eudragit S 100 in the ratio of 1:5 with fixed span 
concentration of 2% but, by varying RPM viz. 1000, 2000 and 2500. 
As the RPM increased, the particle size of the microsphere 
formulations decreased and the percent drug entrapment increased. 
This could be due to the increase in the viscosity of the medium. 
Effect of RPM on mesalazine loaded eudragit L 100 microspheres 
Three formulations F17, F18 and F19 were prepared with 
mesalazine and eudragit L 100 in the ratio of 1:3 with fixed span 
concentration of 2% but, by varying RPM viz. 1000, 2000 and 2500 
respectively. As the RPM increased, the particle size of the 
microsphere formulations decreased, whereas the percent drug 
entrapment increased. This could be due to the increase in the 
viscosity of the medium. 
Effect of concentration of Span 80 on mesalazine loaded 
eudragit L 100 microspheres 
Three formulations F20, F21 and F22 were prepared using 
mesalazine and eudragit L 100 in the ratio of 1:3 and with a fixed 
RPM of 1500 but, by varying span concentration viz. 1%, 1.5% and 
2.5% respectively. As the concentration of span 80 increased, the 
particle size of the microsphere formulations decreased, but after a 
certain extent, the particle size increased. A similar effect was found 
in case of percent drug entrapment which decreased initially and 
later increased. This is due to better stabilisation of internal droplets 
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with an increase of surfactant concentration preventing coalescence. 
Also when more amount of surfactant was added, there is an 
accelerated dispersion of microcapsules in the microencapsulation 
system. 
Characterization of mesalazine microspheres for optimized 
formulations 
The optimised microsphere formulations were characterized for 
parameters such as percentage yield, particle size, percent drug 
entrapment, granular analysis and the results were shown in table 5. 
The percentage yield of microspheres ranged from 87.36% to 
98.78% for formulations prepared with eudragit S 100 and 85.42% 
to 98.59% for formulations prepared with eudragit L 100. The 
particle size was found to be ranging from 227.12±1.4μm to 
378.89±2.5μm for eudragit S 100 microspheres and 230.54±3.4μm 
to the 345.57±2.4μm range for eudragit L 100 microspheres. The 
percent drug entrapment was found to be in the range of 89.78% to 
98.54% for eudragit S 100 microspheres and 84.32% to 98.97% for 
eudragit L 100 microspheres. The flow property was found to be best 
for formulation F16 (23⁰ 45') using eudragit S 100 and for formulation 
F20 (23⁰ 29') using eudragit L 100. Bulk density was found to be least 
for formulation F12 at 0.2800g/cc and maximum for formulation F16 
at 0.4200g/cc. Tap density was found to be in the range of 0.3925g/cc 
to 0.6300g/cc for all the prepared microsphere formulations. The 
bulkiness was observed to be in the range of 1.8308 to 3.5714. The 
Carr’s index was found to be in the range of 22.57% to 42.86% and 
Hausner’s ratio was found to be in the range of 1.2478 to 1.7503 for all 
the prepared microsphere formulations. 
  
Table 5: Characterization of optimised mesalazine microsphere formulations 
Formulation 
code 






















F11 98.78±0.65 259.42±1.4 98.54±0.35 0.384±0.04 0.598±0.03 2.60±0.42 35.76±0.3 1.55±0.4 29⁰ 78' 
F12 91.35±0.34 287.78±3.2 92.54±0.24 0.280±0.04 0.392±0.06 3.57±0.31 22.57±0.4 1.40±0.3 24⁰ 25' 
F13 95.56±0.21 346.67±1.8 94.86±0.39 0.314±0.06 0.448±0.04 3.18±0.28 29.98±0.3 1.42±0.2 25⁰ 26' 
F14 87.36±0.47 378.89±2.5 89.78±0.21 0.318±0.03 0.557±0.05 3.13±0.36 42.86±0.2 1.75±0.4 30⁰ 18' 
F15 90.34±0.39 281.36±0.9 91.35±0.19 0.285±0.04 0.392±0.02 3.50±0.34 27.28±0.6 1.37±0.5 24⁰ 08' 
F16 94.98±0.22 227.12±1.4 97.89±0.41 0.420±0.03 0.630±0.04 2.38±0.43 33.33±0.7 1.54±0.6 23⁰ 45' 
F17 85.42±0.41 345.57±2.4 84.32±0.53 0.359±0.05 0.567±0.04 2.78±0.17 36.74±0.5 1.58±0.4 26⁰ 78' 
F18 92.56±0.30 276.64±2.8 94.58±0.44 0.381±0.06 0.579±0.05 2.62±0.26 34.12±0.6 1.51±0.5 26⁰ 91' 
F19 89.56±0.39 230.54±3.4 91.56±0.37 0.360±0.04 0.478±0.06 2.77±0.19 24.62±0.5 1.32±0.3 28⁰ 54' 
F20 96.52±0.56 298.65±1.6 97.93±0.24 0.546±0.03 0.681±0.04 1.83±0.21 24.78±0.4 1.24±0.3 23⁰ 29' 
F21 93.56±0.73 256.48±2.2 94.35±0.69 0.293±0.02 0.470±0.06 3.40±0.31 37.51±0.6 1.60±0.2 27⁰ 49' 
F22 98.59±0.64 310.48±2.4 98.97±0.36 0.389±0.03 0.545±0.05 2.56±0.37 28.63±0.3 1.40±0.4 24⁰ 36' 
* (n=3); (average±SD) 
 
In vitro drug release studies 
The percentage drug release was found to be best in microsphere 
formulation F13 with 100.51% release and least drug release was 
observed in formulation F16 with 89.72% at the end of 12th hour using 
eudragit S 100 as a polymer. The drug release was found best in 
formulation F20 with 93.42% and least drug release was observed 
with 73.25% in formulation F22 to the end of 12 h using eudragit L 
100 as a polymer. The plot for cumulative drug release profiles for all 
the formulations prepared using eudragit S 100 and L 100 were shown 
in the fig. 7, 8. The drug release for the formulations was found to be 
less than 25% till the end of 4th hour after which there is a rapid 
release of drug by the end of 12 h. This release shows the pH 




Fig. 7: Drug-release profile of formulation with varying surfactant 
concentration and RPM with polymer eudragit S 100 (n=3) 
 
Drug release kinetics 
The best fit model was found to be Peppas for formulations F11, F12, 
F13, F14, F15, F16, F17, F18, F19, F20 and F22, whereas 
formulations F21 showed zero order release kinetics. 
 
Fig. 8: Drug-release profile of formulation with varying 




Table 6 represents the results of stability studies for the prepared 
microsphere formulations. The drug entrapment efficiency and the 
physical appearance of the microspheres were examined for 
formulations F13 for eudragit S 100 and F20 for eudragit L100 at 
various time intervals of 2, 4 and 6 mo by storing them in 
accelerated conditions (40 ° C±2 ° C/75% RH±5%). The results of 
percentage drug entrapment efficiency and physical appearance of 
both the formulations were close to that of initial data with very 
slight variations suggesting that it has an acceptable stability on 
storage. The similarity factor (ƒ2) for a modified release dosage form 
was used as a basis to compare the dissolution profiles of the best 
formulations at 2, 4 and 6 mo with the initial day. The similarity 
factor values for 2, 4 and 6 mo were found to be 67.89, 64.25 and 
60.32 respectively indicating the closest fit to the initial day 
dissolution profile. 
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Table 6: Data for stability study indicating percentage drug content 
Formulation code Percentage drug content 
0 Time  2nd mo 4th mo 6th mo 
F13 100.51±0.75 100.20±0.54 99.94±0.35 99.58±0.49 
F20 93.42±0.95 93.25±1.20 93.02±0.68 92.68±0.35 




Sustained release mesalazine microspheres for colon targeting were 
prepared by a non-aqueous solvent evaporation method using pH 
sensitive polymers such as eudragit S 100 and eudragit L 100. The 
microspheres prepared with polymers eudragit S100 and eudragit L 
100 were found suitable for colonic release of mesalazine resisting 
drug release in gastric medium, minimising release in the upper 
intestinal region and showing maximum release in the colonic region. 
The effect of variable parameters like concentration of span 80 and 
RPM was tested on the best formulation and further characterised. 
Thus the developed formulations prove to be promising for the colon 
targeted drug delivery of mesalazine and thereby facilitating in the 
management of ulcerative colitis and inflammatory bowel disease. 
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